Eli Lilly also agreed to acquire Organovo Holdings' (ONVO) clinical drug development program targeting farnesoid X receptor agonists. In its fourth-quarter, Eli Lilly results exceeded Wall Street ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback